| Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study H Sorbye, S Welin, SW Langer, LW Vestermark, N Holt, P Osterlund, ... Annals of oncology 24 (1), 152-160, 2013 | 1041 | 2013 |
| Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies HT Mouridsen, SW Langer, J Buter, H Eidtmann, G Rosti, M De Wit, ... Annals of Oncology 18 (3), 546-550, 2007 | 230 | 2007 |
| A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis BM Fischer, J Mortensen, SW Langer, A Loft, AK Berthelsen, BL Petersen, ... Annals of Oncology 18 (2), 338-345, 2007 | 202 | 2007 |
| Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors CB Johnbeck, U Knigge, A Loft, AK Berthelsen, J Mortensen, P Oturai, ... Journal of Nuclear Medicine 58 (3), 451-457, 2017 | 196 | 2017 |
| Treatment of anthracycline extravasation with dexrazoxane SW Langer, M Sehested, PB Jensen Clinical Cancer Research 6 (9), 3680-3686, 2000 | 170 | 2000 |
| Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: a pilot study M Quist, M Rørth, S Langer, LW Jones, JH Laursen, H Pappot, ... Lung Cancer 75 (2), 203-208, 2012 | 160 | 2012 |
| 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients A Pfeifer, U Knigge, T Binderup, J Mortensen, P Oturai, A Loft, ... Journal of Nuclear Medicine 56 (6), 847-854, 2015 | 138 | 2015 |
| Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms ET Janson, H Sorbye, S Welin, B Federspiel, H Grønbæk, P Hellman, ... Acta Oncologica 53 (10), 1284-1297, 2014 | 138 | 2014 |
| Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study F Blackhall, K Jao, L Greillier, BC Cho, K Penkov, N Reguart, M Majem, ... Journal of Thoracic Oncology 16 (9), 1547-1558, 2021 | 137 | 2021 |
| Neuroendocrine carcinomas of the gastroenteropancreatic system: a comprehensive review EE Ilett, SW Langer, IH Olsen, B Federspiel, A Kjær, U Knigge Diagnostics 5 (2), 119-176, 2015 | 127 | 2015 |
| The impact of a multidimensional exercise intervention on physical and functional capacity, anxiety, and depression in patients with advanced-stage lung cancer undergoing … M Quist, L Adamsen, M Rørth, JH Laursen, KB Christensen, SW Langer Integrative cancer therapies 14 (4), 341-349, 2015 | 124 | 2015 |
| Dexrazoxane for the treatment of chemotherapy-related side effects SW Langer Cancer management and research, 357-363, 2014 | 117 | 2014 |
| Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: a Nordic multicenter comparative study SP Haugvik, ET Janson, P Österlund, SW Langer, RS Falk, KJ Labori, ... Annals of surgical oncology 23, 1721-1728, 2016 | 101 | 2016 |
| Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice SW Langer, M Sehested, PB Jensen Annals of oncology 12 (3), 405-410, 2001 | 94 | 2001 |
| High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial BH Grønberg, KT Killingberg, Ø Fløtten, OT Brustugun, K Hornslien, ... The Lancet Oncology 22 (3), 321-331, 2021 | 84 | 2021 |
| 64Cu-DOTATATE for noninvasive assessment of atherosclerosis in large arteries and its correlation with risk factors: head-to-head comparison with 68Ga-DOTATOC in 60 patients C Malmberg, RS Ripa, CB Johnbeck, U Knigge, SW Langer, J Mortensen, ... Journal of Nuclear Medicine 56 (12), 1895-1900, 2015 | 82 | 2015 |
| Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone SW Langer, AV Thougaard, M Sehested, PB Jensen Cancer chemotherapy and pharmacology 57, 125-128, 2006 | 81 | 2006 |
| Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas IH Olsen, JB Sørensen, B Federspiel, A Kjaer, CP Hansen, U Knigge, ... The Scientific World Journal 2012, 2012 | 79 | 2012 |
| A consensus-developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations H Elvebakken, A Perren, JY Scoazec, LH Tang, B Federspiel, DS Klimstra, ... Neuroendocrinology 111 (9), 883-894, 2021 | 73 | 2021 |
| 18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study T Binderup, U Knigge, CB Johnbeck, A Loft, AK Berthelsen, P Oturai, ... Journal of Nuclear Medicine 62 (6), 808-815, 2021 | 63* | 2021 |
Tina BinderupSenior Researcher, Rigshospitalet, DenmarkPotvrđena adresa e-pošte na sund.ku.dk
